Atrantil for Intestinal Bacterial Overgrowth

N/A

Waitlist Available

Led By Darren Brenner, MD

Research Sponsored by Northwestern University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up post-treatment (+-3 days)

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing Atrantil, a natural supplement made from peppermint, quebracho tree bark, and horse chestnut. It targets patients with Intestinal Methanogenic Overgrowth (IMO), who suffer from excessive methane production in their gut. Atrantil aims to reduce methane gas, which can help relieve symptoms like bloating and constipation.

Eligible Conditions

Irritable Bowel Syndrome
Small Intestinal Bacterial Overgrowth
SIBO

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change from baseline at four weeks.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change from baseline at four weeks.

This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline at four weeks. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in clinical symptoms of Intestinal Methane Overgrowth as measured by Patient Reported Outcome Measures Information Systems Gastrointestinal Symptoms Scale (PROMIS-GI)

Change in clinical symptoms of Intestinal Methane Overgrowth as measured by daily Numeric Rating Scale (NRS) measuring pain, bloating, distention, and discomfort.

Change in clinical symptoms of Intestinal Methane Overgrowth as measured by the Bristol Stool Scale (BSS)

Secondary study objectives

Change in Quality of life as measured by the PROMIS-Global Health (PROMIS-GH)

Change in methane as measured by hydrogen methane breath-test pre and post-treatment.

Change in quality of life as measured by Short Form- 12.